世界の視神経スペクトラム障害（NMOSD）市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4571
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、109ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、視神経スペクトラム障害（NMOSD）の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（静脈注射、経口、皮下、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・視神経スペクトラム障害（NMOSD）の市場動向
・企業の競争状況、市場シェア
・視神経スペクトラム障害（NMOSD）の種類別市場規模と予測2016-2027（静脈注射、経口、皮下、その他）
・視神経スペクトラム障害（NMOSD）の用途別市場規模と予測2016-2027（病院、クリニック、その他）
・視神経スペクトラム障害（NMOSD）の北米市場規模2016-2027（アメリカ、カナダ）
・視神経スペクトラム障害（NMOSD）の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・視神経スペクトラム障害（NMOSD）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・視神経スペクトラム障害（NMOSD）の中南米市場規模2016-2027（メキシコ、ブラジル）
・視神経スペクトラム障害（NMOSD）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（F. Hoffmann-La Roche Ltd、Alexion Pharmaceuticals、RemeGen、Nihon Pharmaceutical、Harbour BioMed、Lundbeck、Bionure、Opexa Therapeutics、TG Therapeutics、Bio-Thera Solutions、Boston Pharmaceuticals、Cour Pharmaceutical）
・結論

Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks) but, after the initial episode, no recurrence. It is now recognized that most patients satisfying current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months or years.

Market Analysis and Insights: Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
The global Neuromyelitis Optica Spectrum Disorder (NMOSD) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market.

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Scope and Market Size
Neuromyelitis Optica Spectrum Disorder (NMOSD) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Intravenous
Oral
Subcutaneous
Others

Segment by Application
Hospital
Clinic
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
F. Hoffmann-La Roche Ltd
Alexion Pharmaceuticals
RemeGen
Nihon Pharmaceutical
Harbour BioMed
Lundbeck
Bionure
Opexa Therapeutics
TG Therapeutics
Bio-Thera Solutions
Boston Pharmaceuticals
Cour Pharmaceutical

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Intravenous
1.2.3 Oral
1.2.4 Subcutaneous
1.2.5 Others
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Perspective (2016-2027)
2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Growth Trends by Regions
2.2.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Share by Regions (2016-2021)
2.2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Regions (2022-2027)
2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Industry Dynamic
2.3.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends
2.3.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
2.3.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges
2.3.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue
3.1.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue (2016-2021)
3.1.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Players (2016-2021)
3.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue
3.4 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2020
3.5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Players Head office and Area Served
3.6 Key Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Solution and Service
3.7 Date of Enter into Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Type
4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Type (2016-2021)
4.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2022-2027)

5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Application
5.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Application (2016-2021)
5.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
6.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
6.2.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
6.2.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
6.2.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
6.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
6.3.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
6.3.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
6.3.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
6.4 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
6.4.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021)
6.4.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
7.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
7.2.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
7.2.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
7.2.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
7.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
7.3.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
7.3.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
7.3.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
7.4 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
7.4.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021)
7.4.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
8.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
8.2.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
8.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
8.3.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
8.4 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region
8.4.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
9.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
9.2.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
9.2.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
9.2.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
9.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
9.3.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
9.3.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
9.3.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
9.4 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
9.4.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021)
9.4.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
10.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
10.2.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
10.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
10.3.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
10.4 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
10.4.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 F. Hoffmann-La Roche Ltd
11.1.1 F. Hoffmann-La Roche Ltd Company Details
11.1.2 F. Hoffmann-La Roche Ltd Business Overview
11.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.1.4 F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.1.5 F. Hoffmann-La Roche Ltd Recent Development
11.2 Alexion Pharmaceuticals
11.2.1 Alexion Pharmaceuticals Company Details
11.2.2 Alexion Pharmaceuticals Business Overview
11.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.2.4 Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.2.5 Alexion Pharmaceuticals Recent Development
11.3 RemeGen
11.3.1 RemeGen Company Details
11.3.2 RemeGen Business Overview
11.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.3.4 RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.3.5 RemeGen Recent Development
11.4 Nihon Pharmaceutical
11.4.1 Nihon Pharmaceutical Company Details
11.4.2 Nihon Pharmaceutical Business Overview
11.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.4.4 Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.4.5 Nihon Pharmaceutical Recent Development
11.5 Harbour BioMed
11.5.1 Harbour BioMed Company Details
11.5.2 Harbour BioMed Business Overview
11.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.5.4 Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.5.5 Harbour BioMed Recent Development
11.6 Lundbeck
11.6.1 Lundbeck Company Details
11.6.2 Lundbeck Business Overview
11.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.6.4 Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.6.5 Lundbeck Recent Development
11.7 Bionure
11.7.1 Bionure Company Details
11.7.2 Bionure Business Overview
11.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.7.4 Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.7.5 Bionure Recent Development
11.8 Opexa Therapeutics
11.8.1 Opexa Therapeutics Company Details
11.8.2 Opexa Therapeutics Business Overview
11.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.8.4 Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.8.5 Opexa Therapeutics Recent Development
11.9 TG Therapeutics
11.9.1 TG Therapeutics Company Details
11.9.2 TG Therapeutics Business Overview
11.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.9.4 TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.9.5 TG Therapeutics Recent Development
11.10 Bio-Thera Solutions
11.10.1 Bio-Thera Solutions Company Details
11.10.2 Bio-Thera Solutions Business Overview
11.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.10.4 Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.10.5 Bio-Thera Solutions Recent Development
11.11 Boston Pharmaceuticals
11.11.1 Boston Pharmaceuticals Company Details
11.11.2 Boston Pharmaceuticals Business Overview
11.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.11.4 Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.11.5 Boston Pharmaceuticals Recent Development
11.12 Cour Pharmaceutical
11.12.1 Cour Pharmaceutical Company Details
11.12.2 Cour Pharmaceutical Business Overview
11.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.12.4 Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.12.5 Cour Pharmaceutical Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Intravenous
Table 3. Key Players of Oral
Table 4. Key Players of Subcutaneous
Table 5. Key Players of Others
Table 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Regions (2016-2021)
Table 10. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Regions (2022-2027)
Table 12. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends
Table 13. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
Table 14. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges
Table 15. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints
Table 16. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Players (2016-2021)
Table 18. Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) as of 2020)
Table 19. Ranking of Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Solution and Service
Table 23. Date of Enter into Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2016-2021)
Table 27. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Application (2016-2021)
Table 31. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027) & (US$ Million)
Table 63. F. Hoffmann-La Roche Ltd Company Details
Table 64. F. Hoffmann-La Roche Ltd Business Overview
Table 65. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 66. F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 67. F. Hoffmann-La Roche Ltd Recent Development
Table 68. Alexion Pharmaceuticals Company Details
Table 69. Alexion Pharmaceuticals Business Overview
Table 70. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 71. Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 72. Alexion Pharmaceuticals Recent Development
Table 73. RemeGen Company Details
Table 74. RemeGen Business Overview
Table 75. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 76. RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 77. RemeGen Recent Development
Table 78. Nihon Pharmaceutical Company Details
Table 79. Nihon Pharmaceutical Business Overview
Table 80. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 81. Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 82. Nihon Pharmaceutical Recent Development
Table 83. Harbour BioMed Company Details
Table 84. Harbour BioMed Business Overview
Table 85. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 86. Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 87. Harbour BioMed Recent Development
Table 88. Lundbeck Company Details
Table 89. Lundbeck Business Overview
Table 90. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 91. Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 92. Lundbeck Recent Development
Table 93. Bionure Company Details
Table 94. Bionure Business Overview
Table 95. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 96. Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 97. Bionure Recent Development
Table 98. Opexa Therapeutics Company Details
Table 99. Opexa Therapeutics Business Overview
Table 100. Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 101. Opexa Therapeutics Recent Development
Table 102. TG Therapeutics Company Details
Table 103. TG Therapeutics Business Overview
Table 104. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 105. TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 106. TG Therapeutics Recent Development
Table 107. Bio-Thera Solutions Company Details
Table 108. Bio-Thera Solutions Business Overview
Table 109. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 110. Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 111. Bio-Thera Solutions Recent Development
Table 112. Boston Pharmaceuticals Company Details
Table 113. Boston Pharmaceuticals Business Overview
Table 114. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 115. Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 116. Boston Pharmaceuticals Recent Development
Table 117. Cour Pharmaceutical Company Details
Table 118. Cour Pharmaceutical Business Overview
Table 119. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 120. Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 121. Cour Pharmaceutical Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type: 2020 VS 2027
Figure 2. Intravenous Features
Figure 3. Oral Features
Figure 4. Subcutaneous Features
Figure 5. Others Features
Figure 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application: 2020 VS 2027
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Others Case Studies
Figure 10. Neuromyelitis Optica Spectrum Disorder (NMOSD) Report Years Considered
Figure 11. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Regions: 2020 VS 2027
Figure 14. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Regions (2022-2027)
Figure 15. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Players in 2020
Figure 16. Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2020
Figure 18. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2016-2021)
Figure 19. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2022-2027)
Figure 20. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
Figure 22. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
Figure 23. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2016-2027)
Figure 24. United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
Figure 28. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
Figure 29. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2016-2027)
Figure 30. Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region (2016-2027)
Figure 40. China Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
Figure 48. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
Figure 49. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2016-2027)
Figure 50. Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2016-2027)
Figure 56. Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 60. Alexion Pharmaceuticals Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 61. RemeGen Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 62. Nihon Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 63. Harbour BioMed Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 64. Lundbeck Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 65. Bionure Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 66. Opexa Therapeutics Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 67. TG Therapeutics Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 68. Bio-Thera Solutions Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 69. Boston Pharmaceuticals Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 70. Cour Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

以下、関連資料のご紹介

世界の視神経治療市場規模・現状・予測（2021年-2027年）

Global Neuromyelitis Optica Therapy Market Size, Status and Forecast 2021-2027
QFJ1-5882 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、視神経治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（糖質コルチコイド、免疫療法、その他）、用途別市場規模（急性発作、寛解予防治療）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、...

世界のデビック症候群（視神経脊髄炎）治療市場規模・現状・予測（2021年-2027年）

Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4118 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、デビック症候群（視神経脊髄炎）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（エクリズマブ、メチルプレドニゾロン、アザチオプリン、ミコフェノール酸モフェチル、リツキシマブ）、用途別市場規模（病院、...

世界のCDKL5欠乏症（CDD）市場規模・現状・予測（2021年-2027年）

Global CDKL5 Deficiency Disorder (CDD) Market Size, Status and Forecast 2021-2027
QFJ1-3983 2021年6月 89Pages
QYResearch社発行の本調査レポートでは、CDKL5欠乏症（CDD）の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（従来型医薬品、新型医薬品）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中...

世界の月経前不快気分障害（PMDD）市場規模・現状・予測（2021年-2027年）

Global Premenstrual Dysphoric Disorder (PMDD) Market Size, Status and Forecast 2021-2027
QFJ1-4754 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、月経前不快気分障害（PMDD）の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（錠剤、注入剤、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本...

世界の甲状腺障害市場規模・現状・予測（2021年-2027年）

Global Thyroid Disorder Market Size, Status and Forecast 2021-2027
QFJ1-6041 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、甲状腺障害の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（甲状腺機能低下症、甲状腺機能亢進症）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓...

世界のHPV関連疾患市場規模・現状・予測（2021年-2027年）

Global HPV Associated Disorder Market Size, Status and Forecast 2021-2027
QFJ1-4327 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、HPV関連疾患の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（予防、治療）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、イ...

世界の強迫性障害治療薬市場規模・現状・予測（2021年-2027年）

Global Obsessive-Compulsive Disorder Drugs Market Size, Status and Forecast 2021-2027
QFJ1-5903 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、強迫性障害治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（SSRI、TCA、その他）、用途別市場規模（病院、クリニック、研究所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、...

世界の神経疾患診断市場規模・現状・予測（2021年-2027年）

Global Neurological Disorder Diagnostics Market Size, Status and Forecast 2021-2027
QFJ1-4569 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、神経疾患診断の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（イメージング技術、体外診断技術）、用途別市場規模（病院・クリニック、診断センター、外来診療センター）、主要地域別市場規模（北米、アメリカ、欧...

世界のオピオイド使用障害市場規模・現状・予測（2021年-2027年）

Global Opioid Use Disorder Market Size, Status and Forecast 2021-2027
QFJ1-4617 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、オピオイド使用障害の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ブプレノルフィン、メタドン、ナルトレキソン）、用途別市場規模（中等度疼痛治療、重度疼痛治療）、主要地域別市場規模（北米、アメリカ、欧州...

世界の物質使用障害治療市場規模・現状・予測（2021年-2027年）

Global Substance Use Disorder Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4914 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、物質使用障害治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アルコール乱用治療、ニコチン乱用治療、薬物乱用治療）、用途別市場規模（病院、クリニック、在宅医療設備）、主要地域別市場規模（北米、アメリ...

世界の視神経治療市場規模・現状・予測（2021年-2027年） Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and somet…
世界のデビック症候群（視神経脊髄炎）治療市場規模・現状・予測（2021年-2027年） Devic’s syndrome is also known as neuromyelitis optica which is a central nervous system disorder that specifically affects eye nerves and spinal cord. Market Analysis and Insights: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market The global Devic’s Syndrome (Neuromyelitis Optica) Tre…
世界のCDKL5欠乏症（CDD）市場規模・現状・予測（2021年-2027年） CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy (DEE), X-linked genetic condition which results in early-onset, difficult to control seizures and severe neuro-developmental impairment. CDKL5 stands for cyclin-dependent kinase-like 5 and mutations in this gene were fi…
世界の月経前不快気分障害（PMDD）市場規模・現状・予測（2021年-2027年） Premenstrual dysphoric disorder (PMDD) is a health problem that is similar to premenstrual syndrome (PMS) but is more serious. PMDD causes severe irritability, depression, or anxiety in the week or two before your period starts. Symptoms usually go away two to three days after your period starts. Ma…
世界の強迫性障害治療薬市場規模・現状・予測（2021年-2027年） Obsessive–compulsive disorder (OCD) is a mental disorder in which a person feels the need to perform certain routines repeatedly (called "compulsions"), or has certain thoughts repeatedly (called "obsessions"). The launch of new molecules is one of the primary drivers for the obsessive-compulsive di…